FDA approves Jazz Pharmaceuticals' Ziihera for first-line HER2+ gastroesophageal cancer
The FDA approved two first-line Ziihera regimens for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, expanding Jazz Pharmaceuticals’ commercial opportunity through its partnership with Zymeworks. The approval adds a near-term product catalyst for Jazz, but the available financial data still show a business with a -8.3% net margin and $-5.84 diluted EPS.
STOCK PHOTO · NOTHING AHEADThe story
Jazz Pharmaceuticals said the U.S. Food and Drug Administration approved Ziihera in combination with Tevimbra plus chemotherapy, and Ziihera with chemotherapy, for first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma. Zymeworks announced the decision on Aug. 25, 2026, identifying Jazz as its partner for the approved asset.
The decision directly connects Jazz, Zymeworks and BeiGene, whose Tevimbra is part of one of the approved regimens. It gives Ziihera a first-line indication in a serious oncology setting and broadens the commercial use cases that Jazz can pursue under its partnership with Zymeworks.
The next read-through will be the launch and uptake of the two regimens, including how oncologists divide use between the Tevimbra-containing option and Ziihera plus chemotherapy. Jazz’s reported FY2025 revenue was $4.3B, up 4.9% YoY, but the company also reported a -8.3% net margin and $-5.84 diluted EPS; the approval therefore creates a product catalyst without, on the supplied figures, establishing its eventual earnings contribution. No dated follow-up event was provided.
Our read · Tue, Aug 25
The FDA approved two first-line Ziihera regimens for JAZZ in adults with HER2-positive advanced gastroesophageal adenocarcinoma.
Why. The approval creates a concrete commercial expansion for Jazz, but the supplied financial profile does not yet show how much revenue or earnings Ziihera can add: FY2025 revenue was $4.3B, up 4.9% YoY, alongside a -8.3% net margin and $-5.84 diluted EPS. Without a dated forward event or launch metrics, the evidence supports a positive company read but not a conviction trade setup.
Both cases
What could change this view: The trade weakens if launch uptake is slow or if the approval does not translate into a material contribution against Jazz’s -8.3% net margin and $-5.84 diluted EPS.
Who reported it · 1
Keep reading
Latest on the Wire
Trump calls Russian missiles in Poland mistakes before fresh incursionAmazon nears $7.5bn Decart deal as AWS takes on Nvidia in AI computingRussian cargo ship Sparta II reportedly hit by drones near FinlandBTCS warns $54 million Aave loan faces liquidation as ether fallsIntesa Sanpaolo launches €34.5bn cash-and-share offer for Monte dei PaschiContinue on the Wire →Latest on the Wire
Nvidia tumbles as US tech stocks enter bear market on AI spending fearsTrump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on ThursdayAbout this report
Reported by GlobeNewswire as U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →